Bisphosphonates: Issues of Long-Term Therapy and Evidence of Efficacy in Real Clinical Practice

I.Yu. Holovach


Osteoporosis is a disease of great social importance. Its treatment is a complicated problem and is associated with low compliance of patients and a risk for adverse reactions. First-line drugs are bisphosphonates, which have been used in the clinical practice for over 15 years. During this period, there were accumulated the data on adverse events, the incidence of which was very low, or which were not detected at all during the studies on the efficacy and safety of bisphosphonates. Today, it is raised the question about which categories of patients should use bisphosphonate therapy, for how long the drugs of this group needed to be administered, is it possible to stop taking bisphosphonates for a time without increasing the risk of fractures. An algorithm for a long-term treatment of osteoporosis using bisphosphonates and principles of monitoring the effectiveness of therapy are presented. The article describes two clinical cases of ibandronic acid application for the prevention and treatment of postmenopausal osteoporosis with a good clinical effect. The data on changes in bone mineral density during the observation from 12 to 27 months, as well as the risk of fractures by FRAX system are provided. Clinical experience shows that the use of Bonviva in the combination treatment of postmenopausal osteoporosis contributes not only the progressive increase in bone mineral density at the lumbar spine and proximal femur, but also reduces the risk of vertebral fractures.


osteoporosis; bisphosphonates; treatment duration; drug holidays; efficiency; ibandronate; clinical cases


Белая Ж.Е., Рожинская Л.Я. Рациональный выбор фармакотерапии постменопаузального остеопороза. Эффективность и безопасность бонвивы: обзор за восемь лет применения // Остеопороз и остеопатии. 2013; 2: 22-30.

Головач И.Ю., Кочиш А.Ю. Проблема атипичных переломов бедра на фоне приема бисфосфонатов: стратегические и тактические вопросы лечения остеопороза // Рациональная фармакотерапия. 2013; 4(29): 29-36.

Головач І.Ю. Лікування остеопорозу у контексті профілактики переломів: впровадження даних доказової медицини в клінічну практику. У ракурсі — ібандронова кислота // Травма. 2013; 14(1): 57-64.

Ершова О.Б., Белова К.Ю., Назарова А.В. Длительное применение препарата Бонвива® для лечения постменопаузального остеопороза: новые данные // Боль. Суставы. Позвоночник. 2013; 1(9): 35-38.

Кочиш А.Ю., Иванов С.Н. Случай остеонекроза верхней челюсти у пациентки с постменопаузальным остеопорозом на фоне длительного лечения антирезорбтивными препаратами // Фарматека. 2015; 5: 83-87.

Мкртумян А.М., Козлова М.В., Белякова А.С. Бонвива — мощный антиостеопоротический бисфосфонат // Эффективная фармакотерапия. 2016; 4: 32-38.

Allen M.R. Skeletal accumulation of bisphosphonates: implications for osteoporosis treatment // Expert Opin. Drug Metab. Toxicol. 2008 Nov; 4(11): 1371-8. doi: 10.1517/17425255.4.11.1371.

Barrett J., Worth E., Bauss F. Ibandronate: a clinical pharmacological and pharmacokinetic update // J. Clin. Pharmacol. 2004; 44: 951-965.

Black D.M., Reid I.R., Cauley J.A. et al. The Effect of 6 versus 9 Years of Zoledronic Acid Treatment in Osteoporosis: A Randomized Second Extension to the HORIZON — Pivotal Fracture Trial (PFT) // J. Bone Miner. Res. 2015; 30(5): 934-944. doi: 10.1002/jbmr.2442.

Bone H.G., Hosking D., Devogelaer J.-P. et al. Alendronate Phase III Osteoporosis Treatment Study Group Ten years’ experience with alendronate for osteoporosis in postmenopausal women // N. Engl. J. Med. 2004; 350: 1189-1199.

Burr D.B., Diab T., Koivunemi A. et al. Effects of 1 to 3 years’ treatment with alendronate on mechanical properties of the femoral shaft in a canine model: implications for subtrochanteric femoral fracture risk // J. Orthop. Res. 2009; 27 (10): 1288-1292. doi: 10.1002/jor.20895.

Cosman F., de Beur S.L., LeBoff M.S. Clinician’s Guide to Prevention and Treatment of Osteoporosis // Osteoporos. Int. 2014; 25(10): 2359-2381. doi: 10.1007/s00198-014-2794-2.

Delmas P.D., Adami S., Strugala C. et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study // Arthr. Rheum. 2006; 54: 1838-1846.

Diab D.L., Watts N.B. Bisphosphonate drug holiday: who, when and how long // Ther. Adv. Musculoskelet. Dis. 2013; 5(3): 107-111. doi: 10.1177/1759720X13477714.

Eisman J.A., Civitelli R., Adami S. et al. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study // J. Rheum. 2008; 35 (3): 488-497.

Matthew E.L., Robert A.P., Robert E.F. Farnesyl Diphosphate Synthase: a novel genotype association with bone mineral density in elderly women // NIH Public Access. 2007; 57(3): 247-252. doi: 10.1016/j.maturitas.2007.01.005.

Mellstrom D.D., Sorensen O.H., Goemaere S. et al. Seven years of treatment with risedronate in women with postmenopausal osteoporosis // Calcif. Tissue Int. 2004; 75: 462-468.

Ott S.M. What is the optimal duration of bisphosphonate therapy? // Cleveland Clin. J. Med. 2011; 78 (9): 619-630. doi: 10.3949/ccjm.78a.11022.

Ro C., Cooper O. Bisphosphonate drug holiday: choosing appropriate candidates // Curr. Osteoporos. Rep. 2013; 11(1): 45-51. doi: 10.1007/s11914-012-0129-9.

Rogers M.J., Crockett J.C., Coxon F.P., Mönkkönen J. Biochemical and molecular mechanisms of action of bisphosphonates // Bone. 2011; 49(1): 34-41. doi: 10.1016/j.bone.2010.11.008.

Rogers M.J. New insights into the molecular mechanisms of action of bisphosphonates // Curr. Pharm. Des. 2003; 9 (32): 2643-2658.

Stakkestad J.A., Lakatos P., Lorenc R. et al. Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long-term extension // Clin. Rheum. 2008; 27 (8): 955-960.

Watts N.B., Diab D.L. Long-term use of bisphosphonates in osteoporosis // J. Clin. Endocrinol. Metab. 2010; 95(4): 1555-1565. doi: 10.1210/jc.2009-1947.

Copyright (c) 2016 TRAUMA

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


© Publishing House Zaslavsky, 1997-2018


   Seo анализ сайта